{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:28:11Z","timestamp":1792859291645,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmoop.2025.105556","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:46:17Z","timestamp":1756485977000},"page":"105556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4546-547X","authenticated-orcid":false,"given":"E.","family":"Vita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mastrantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"D\u2019Auria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Monaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Troisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cosmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Polidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Di Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"De Paolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Trisolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cancellieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.esmoop.2025.105556_bib1","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.2174\/0929867324666170911170554","article-title":"NRG1-ErbB lost in translation: a new paradigm for lung cancer?","volume":"24","author":"Trombetta","year":"2017","journal-title":"Curr Med Chem"},{"issue":"6454","key":"10.1016\/j.esmoop.2025.105556_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/366473a0","article-title":"Heregulin induces tyrosine phosphorylation of HER4\/p180erbB4","volume":"366","author":"Plowman","year":"1993","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105556_bib3","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1128\/MCB.17.7.4007","article-title":"Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus","volume":"17","author":"Busfield","year":"1997","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105556_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0092-8674(92)90131-U","article-title":"Isolation of the neu\/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells","volume":"69","author":"Peles","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2025.105556_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/pcm-23-2","article-title":"NRG1 fusions in non-small cell lung cancer: a narrative review on biology, detection and therapy","volume":"6","author":"Muscarella","year":"2023","journal-title":"Precis Cancer Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105556_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0014-4827(02)00102-7","article-title":"Neuregulins: functions, forms, and signaling strategies","volume":"284","author":"Falls","year":"2003","journal-title":"Exp Cell Res"},{"issue":"41","key":"10.1016\/j.esmoop.2025.105556_bib7","doi-asserted-by":"crossref","first-page":"24604","DOI":"10.1074\/jbc.270.41.24604","article-title":"Binding of neu differentiation factor with the extracellular domain of Her2 and Her3","volume":"270","author":"Horan","year":"1995","journal-title":"J Biol Chem"},{"issue":"47","key":"10.1016\/j.esmoop.2025.105556_bib8","doi-asserted-by":"crossref","first-page":"44266","DOI":"10.1074\/jbc.M105428200","article-title":"Identification of a heregulin binding site in HER3 extracellular domain","volume":"276","author":"Singer","year":"2001","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105556_bib9","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","article-title":"Detection of NRG1 gene fusions in solid tumors","volume":"25","author":"Jonna","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105556_bib10","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.20.03307","article-title":"Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry","volume":"39","author":"Drilon","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105556_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4143\/crt.2023.682","article-title":"Clinicopathological characteristics of NRG1 fusion-positive solid tumors in Korean patients","volume":"55","author":"Cha","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105556_bib12","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.3390\/cancers13205038","article-title":"Neuregulin 1 gene (NRG1). A potentially new targetable alteration for the treatment of lung cancer","volume":"13","author":"Rosas","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105556_bib13","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1093\/annonc\/mdx523","article-title":"Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer","volume":"28","author":"Jones","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105556_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/2159-8290.CD-13-0633","article-title":"CD74-NRG1 fusions in lung adenocarcinoma","volume":"4","author":"Fernandez-Cuesta","year":"2014","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105556_bib15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105556_bib16","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105556_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105556_bib18","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1634\/theoncologist.2017-0659","article-title":"The eighth edition of TNM staging of lung cancer: reference chart and diagrams","volume":"23","author":"Lababede","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2025.105556_bib19","article-title":"Impact of comprehensive genome profiling on the management of advanced non\u2013small cell lung cancer: preliminary results from the lung cancer cohort of the FPG500 program","volume":"8","author":"Vitale","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105556_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104090","article-title":"Actionable mutations in early-stage ovarian cancer according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): a descriptive analysis on a large prospective cohort","volume":"10","author":"Camarda","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2025.105556_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.esmoop.2025.105556_bib23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.esmoop.2025.105556_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2025.105556_bib25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/spe.4380211102","article-title":"Graph drawing by force-directed placement","volume":"21","author":"Fruchterman","year":"1991","journal-title":"Softw Pract Exper"},{"key":"10.1016\/j.esmoop.2025.105556_bib26","doi-asserted-by":"crossref","unstructured":"Sabari JK, Yu HA, Mahadevia P, et al. Overall survival after treatment with first-line osimertinib for EGFR-mutant advanced NSCLC in the US. Paper presented at the WCLC 2024. EP.12A.03.","DOI":"10.1016\/j.jtho.2024.09.1162"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105556_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105556_bib28","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105556_bib29","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105556_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105556_bib31","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-18-0450","article-title":"A combination of approved antibodies overcomes resistance of lung cancer to osimertinib by blocking bypass pathways","volume":"24","author":"Romaniello","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105556_bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-21-3359","article-title":"HER3 augmentation via blockade of EGFR\/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer","volume":"28","author":"Yonesaka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105556_bib33","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/onc.2015.142","article-title":"Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib","volume":"35","author":"Yonesaka","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2025.105556_bib34","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/jco.2014.32.15_suppl.8045","article-title":"Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)","volume":"32","author":"von Pawel","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105556_bib35","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","article-title":"A novel HER3-targeting antibody\u2013drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization","volume":"25","author":"Hashimoto","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105556_bib36","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41388-018-0517-4","article-title":"An HER3-targeting antibody\u2013drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC","volume":"38","author":"Yonesaka","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2025.105556_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor\u2013resistant, EGFR-mutated non\u2013small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2025.105556_bib38","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105556_bib39","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","journal-title":"Future Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:16Z","timestamp":1762598656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2059702925014255"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105556","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105556"}}